Key Takeaways
- • Venture capital is shifting toward active company-building models where investors identify market problems, validate opportunities, and either recruit entrepreneurs or back existing founders—fundamentally changing the traditional pattern-recognition approach that starts with founder-led problem identification.
- • Multiple operational support models are emerging simultaneously including platform teams for talent recruitment and market expansion, specialized service providers for branding and go-to-market strategy, and firms institutionalizing the entire company-building process alongside founders.
- • W Health Ventures and Redesign Health exemplify the new model, with W Health validating unmet healthcare needs before company formation, and Redesign Health combining company creation with an operating platform providing entrepreneurs access to expertise, customers, and strategic partners.
- • The underlying ambition is consistent across variants: investors are moving beyond capital provision to answer how they can contribute operational value and strategic direction to portfolio companies, representing a fundamental recalibration of the venture capital value proposition.
Summary
Venture capital is undergoing a systematic transformation in how firms structure their involvement with portfolio companies, moving away from the traditional model of passive capital deployment toward entrepreneurs. Rather than waiting for founders to identify problems and demonstrate early traction, a growing cohort of venture investors is now applying systematic discipline to problem identification itself, validating market opportunities before company formation occurs.
According to Avik Ashar, an operator and investor with experience across multiple startups, venture building represents one expression of a broader structural shift. The traditional model begins with founder-identified problems; the emerging model begins with market-identified problems, validates the opportunity, and then either identifies existing founders working on the problem or recruits entrepreneurs to build the company. This inversion of the founding sequence reflects a fundamental reorganization of venture capital's role in the startup ecosystem.
The evolution is not monolithic. Investors are experimenting with multiple operational support architectures to extend their influence beyond capital. Some firms have built platform teams providing portfolio companies with talent recruitment, market expansion guidance, and regulatory navigation support. Others have specialized in discrete functions such as branding, hiring strategies, or go-to-market execution. More recently, a subset of firms has begun institutionalizing the company-building process itself, creating repeatable systems for identifying problems, validating opportunities, and operationalizing solutions.
Specific implementations demonstrate the diversity within this broader trend. W Health Ventures operates by identifying unmet healthcare market needs, validating those needs, and then determining whether company creation is warranted. Redesign Health combines company creation capabilities with an operating platform that provides entrepreneurs direct access to expertise, customer relationships, and strategic partnerships. Both models share the common objective articulated by Ashar: contributing value beyond capital deployment to accelerate company building and reduce execution risk.
This experimental phase represents a material shift in how venture capital allocates its resources and structure, with institutional implications for deal sourcing, founder recruitment, portfolio support, and ultimately the velocity at which new companies move from concept validation to market scale.
According to Avik Ashar, an operator and investor with experience across multiple startups, venture building represents one expression of a broader structural shift. The traditional model begins with founder-identified problems; the emerging model begins with market-identified problems, validates the opportunity, and then either identifies existing founders working on the problem or recruits entrepreneurs to build the company. This inversion of the founding sequence reflects a fundamental reorganization of venture capital's role in the startup ecosystem.
The evolution is not monolithic. Investors are experimenting with multiple operational support architectures to extend their influence beyond capital. Some firms have built platform teams providing portfolio companies with talent recruitment, market expansion guidance, and regulatory navigation support. Others have specialized in discrete functions such as branding, hiring strategies, or go-to-market execution. More recently, a subset of firms has begun institutionalizing the company-building process itself, creating repeatable systems for identifying problems, validating opportunities, and operationalizing solutions.
Specific implementations demonstrate the diversity within this broader trend. W Health Ventures operates by identifying unmet healthcare market needs, validating those needs, and then determining whether company creation is warranted. Redesign Health combines company creation capabilities with an operating platform that provides entrepreneurs direct access to expertise, customer relationships, and strategic partnerships. Both models share the common objective articulated by Ashar: contributing value beyond capital deployment to accelerate company building and reduce execution risk.
This experimental phase represents a material shift in how venture capital allocates its resources and structure, with institutional implications for deal sourcing, founder recruitment, portfolio support, and ultimately the velocity at which new companies move from concept validation to market scale.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.